ANIP · Nasdaq

ANI PHARMACEUTICALS INC

Pharmaceutical Preparations

Listing type has not been classified. Company financial ratios are not specific to a share class. CIK 0001023024

Dividend overview

Latest reported dividend

Not available

No event collected.

Next announced payment

Not available

No future payment is present in our collected records.

Ex-dividend date

Not reported

For the next collected payment. An unreported date is not inferred from the record date.

Announced dates and amounts may change. Verify current details with the issuer and your broker before acting.

Cash flow & dividend coverage

Cash payout ratio

1.5%

Annual cash dividends ÷ net income.

FCF payout ratio

0.7%

Annual cash dividends ÷ (operating cash flow − PP&E expenditures).

Company-level · annual period Jan 1, 2025 – Dec 31, 2025. Metric date: Oct 21, 2026. Calculated: 2026-10-21T16:56:24.441Z (UTC). Underlying filing

These ratios relate cash dividends paid by the company to its earnings and free cash flow for the stated period. They are not dividend yields or measures of a guaranteed future payout.

Payout ratios describe historical financial results and do not guarantee future dividends. Read the calculation rules.

Cash-dividend numerator: Total cash dividends. Total cash dividends may include more than the common-share distribution.

Dividend history

No matching dividend events have been collected. This does not establish that the company pays no dividend.

Financial context

Company financials →

Annual net income

Reported annual periods; USD. Negative values extend below the baseline.

Selected annual US-GAAP cash-flow and earnings facts · USD
Reporting period	Measure	USD millions	Filing
Dec 31, 2025From Jan 1, 2025	Operating cash flow	185.2	SEC filingFeb 27, 2026
Dec 31, 2025From Jan 1, 2025	Net income	78.3	SEC filingFeb 27, 2026
Dec 31, 2025From Jan 1, 2025	Total cash dividends	1.2	SEC filingFeb 27, 2026
Dec 31, 2025From Jan 1, 2025	Capital expenditures (PP&E)	13.8	SEC filingFeb 27, 2026
Dec 31, 2024From Jan 1, 2024	Operating cash flow	64.0	SEC filingFeb 27, 2026
Dec 31, 2024From Jan 1, 2024	Net income	-18.5	SEC filingFeb 27, 2026
Dec 31, 2024From Jan 1, 2024	Total cash dividends	1.6	SEC filingFeb 27, 2026
Dec 31, 2024From Jan 1, 2024	Capital expenditures (PP&E)	16.2	SEC filingFeb 27, 2026
Dec 31, 2023From Jan 1, 2023	Operating cash flow	119.0	SEC filingFeb 27, 2026
Dec 31, 2023From Jan 1, 2023	Net income	18.8	SEC filingFeb 27, 2026
Dec 31, 2023From Jan 1, 2023	Total cash dividends	1.6	SEC filingFeb 27, 2026
Dec 31, 2023From Jan 1, 2023	Capital expenditures (PP&E)	8.9	SEC filingFeb 27, 2026
Dec 31, 2022From Jan 1, 2022	Operating cash flow	-31.2	SEC filingFeb 28, 2025
Dec 31, 2022From Jan 1, 2022	Net income	-47.9	SEC filingFeb 28, 2025
Dec 31, 2022From Jan 1, 2022	Total cash dividends	1.6	SEC filingFeb 28, 2025
Dec 31, 2022From Jan 1, 2022	Capital expenditures (PP&E)	8.9	SEC filingFeb 28, 2025
Dec 31, 2021From Jan 1, 2021	Operating cash flow	3.3	SEC filingFeb 29, 2024
Dec 31, 2021From Jan 1, 2021	Net income	-42.6	SEC filingFeb 29, 2024
Dec 31, 2021From Jan 1, 2021	Total cash dividends	0.2	SEC filingFeb 29, 2024
Dec 31, 2021From Jan 1, 2021	Capital expenditures (PP&E)	2.6	SEC filingFeb 29, 2024

Latest filed value per tag and exact annual period, within the last seven years. Common-stock and total cash dividends are separate measures; do not add them together. These selected facts are not a complete financial statement.

Read the numbers in context

A higher payout ratio can reflect a larger dividend, lower earnings, or both. Capital spending also affects the FCF denominator. The accounting context matters, especially for financial firms, REITs, and business development companies.

Understand cash payout ratios · Regular vs. special dividends

Sources & corrections

Source: collected SEC filings. USYieldHub is not affiliated with or endorsed by the SEC or this issuer. Coverage is incomplete; amounts may be unadjusted for splits.

Data coverage · Report a data error · Compare this company